The vaccine builds on the company's previously approved vaccine by including seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.
The vaccine builds on the company’s previously approved vaccine by including seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.
Read More
Pfizer’s Prevnar 20 pneumococcal vaccine can be safely co-administered with the Pfizer-BioNTech COVID-19 vaccine, according to a Phase 3 study.
Read More
